Citations

Clear

1446 citation(s) found for "Howard, F".

Three approaches to determining clinically meaningful benefit on the Cohen‐Mansfield Agitation Inventory in dementia clinical trials for agitation
Liu, Kathy , Ivenso, Chineze , Rapaport, Penny , Reeves, Suzanne , Schneider, Lon S. , Group, Agitation MCID Study, Howard, Robert, Howard, Robert , Liu, Kathy Y , Reeves, Suzanne , Howard, Rebecca, Banerjee, Sube , Lapid, Maria I. , Group, Agitation MCID Study, Howard, Robert

Mayo Clinic

Alzheimer's & Dementia: Translational Research & Clinical Interventions | May 15, 2025 | Volume: 11 | Issue: 2 | Pages: No page available

10.1002/trc2.70099 | PMID 40376142 Get It

Abstract INTRODUCTION There is a need to understand the clinical meaningfulness of symptom score changes in treatment trials of dementia‐related agitation. We estimated minimal clinically important differences (MCIDs) for commonly employed agitation scales and contextualized their clinical application. METHODS We employed anchor‐ and distribution‐based approaches to determine changes in scores corresponding to minimal symptom improvement. An opinion‐based approach assessed expert clinicians’ agreement on the meaningfulness of score changes through three clinical vignettes. RESULTS Minimal symptom improvement for Cohen‐Mansfield Agitation Inventory total score ranged from −4 (over <1 month) to −11 (over 1 to 3 months) points. Greater symptom severity correlated with higher MCID estimates. The clinical importance of score changes was influenced by treatment duration, pharmacological side effects, and impacts on caregiver distress/time resources. DISCUSSION The clinical meaningfulness of agitation scale MCIDs is influenced by trial‐specific and clinical factors. Shorter trial durations and measuring caregiver distress/time resources enhance the clinical interpretation of agitation treatment outcomes. Highlights For the CMAI total score, the MCID was −4 points over shorter time scales and −11 points for longer time scales. Worse agitation severity was associated with higher MCID estimates. There was high expert consensus that a noticeable treatment benefit was not worthwhile if it occurred after 12 weeks or had no impact on caregiver/staff distress/time resources.
Differences in COVID-19 Vaccination Behaviors Among Adults With Versus Without Chronic Lower Respiratory Diseases: The C4R Study
Lawin, K., Norwood, Arnita F. , Stukovsky, Karen Hinckley , Elkind, Mitchell S, Ortega, Victor E. , Lopez, Victor , Zhang, Ying , Fretts, Amanda M. , Oelsner, Elizabeth C. , Oelsner, Elizabeth C , Wang, Timothy C. , Lawin, K., Kucharska‐Newton, Anna , Demmer, Ryan T. , Jacobs, David R. , Regan, Elizabeth Anne , Lee, Joyce , Xanthakis, Vanessa , Isasi, Carmen R. , Kanaya, Alka M , Post, Wendy S. , Howard, Virginia J. , Lopez, V., Balte, Pallavi

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A7464-A7464

10.1164/ajrccm.2025.211.abstracts.a7464 Get It

Abstract RATIONALE: Chronic lower respiratory diseases (CLRD) confer higher risks from respiratory viral infections, hence CLRD patients are prioritized for influenza, pneumococcal, and COVID-19 vaccination. Nonetheless, vaccine deferral and declination remain common. Given that COVID-19 vaccination is particularly polarizing, and attitudes toward it may differ from other vaccines, we assessed COVID-19 vaccination behaviors and attitudes in adults with versus without CLRD and/or smoking history, which is strongly associated with CLRD risk. METHODS: We pooled data from 10 cohorts participating in the Collaborative Cohort of Cohorts for COVID-19 Research (C4R) that collected pre-pandemic data on self-reported physician diagnosis of asthma or COPD. C4R assessed COVID-19 vaccination status through three waves of standardized questionnaires (2020-2022, 2021-2023, 2023-2024). Prompt COVID-19 vaccination was defined as self-report of receiving at least one COVID-19 vaccine by May 1, 2021. Cumulative COVID-19 vaccine count was self-reported on the Wave 3 Questionnaire. Vaccine attitudes and receipt of influenza and/or pneumococcal vaccines were self-reported on the Wave 1 or 2 Questionnaire. Age-adjusted Poisson regression was used to test associations of vaccination behaviors with CLRD and smoking status at the most recent pre-pandemic exam. RESULTS: Of 20,034 participants (pre-pandemic COPD, 9.3%; asthma, 11.7%; current smoking, 13.4%; former smoking, 36.3%), 64.2% reported prompt COVID-19 vaccination. Among the subset of 10,626 participants completing the Wave 3 Questionnaire in 2023-24, the median COVID-19 vaccine count was 3 (Q1:2, Q3:4). Compared to participants without CLRD, prompt vaccination was more likely in those with asthma (RR=1.04, 95%CI:1.01-1.07, p=0.008) and less likely with COPD (RR=0.94, 95%CI:0.91-0.98, p=0.001), but there were no differences in doses for asthma and COPD. Compared to never smokers, former smoking participants were more likely to receive prompt vaccination (RR=1.11, 95%CI:1.08-1.13, p&lt;0.0001) and more vaccine doses (RR=1.03, 95%CI:1.01-1.05, p=0.015); conversely, current smoking was inversely associated with prompt vaccination (RR=0.94, 95%CI:0.91-0.97, p=0.001) and was associated with fewer doses (RR=0.93, 95%CI:0.89-0.96, p&lt;0.0001). Participants with CLRD versus without CLRD were more likely to report receiving influenza and pneumococcal vaccines, but they were more likely to believe that vaccines are unsafe or ineffective (figure). CONCLUSIONS: COPD was associated with lower likelihood of prompt COVID-19 vaccination. Current smoking was associated with both lower likelihood of prompt COVID-19 vaccination and a lower number of COVID-19 vaccine doses by 2023-24. These associations may be partly attributed to negative vaccine attitudes and beliefs. How the COVID-19 pandemic may have influenced vaccine behaviors and attitudes merits additional study.
Male Survival Disadvantage in Pulmonary Hypertension in the PVRI Godeep Meta-registry
Annis, Jeffrey , Meike, F., Wilhelm, Jochen , Kiely, David G. , Balasubramanian, A., Eichstaedt, Christina A. , Zamanian, Roham T. , Elwing, Jean , Pepke-Zaba, J., Hernandez, Nadia , Frauendorf, Marlize , Williams, Paul , Anthi, Anastasia , Dima, Efrossini, Majeed, Rehan, Tello, Khodr , Kiely, David , Yogeswaran, Athiththan , Howard, Luke , Lawrie, Allan , Wilkins, Martin R. , Balasubramanian, A. , Hassoun, Paul M. , Grünig, Ekkehard , Sweatt, Andrew J. , Kovács, Gábor , Olschewski, Horst , Ghouleh, Imad Al , Chan, Stephen Y. , Jose, Arun , Cannon, J., Pepke-Zaba, J., Frantz, Robert P. , Sіrenko, Yu.M. , Torbas, O.O. , Sahay, Sandeep , Hernandez, N., Arvanitaki, Alexandra , Giannakoulas, George , Sabbour, Hani Mohamed , Saleh, Khaled Musa Mohammad , Ghio, Stefano , Scelsi, Laura , Majeed, R., Ghofrani, Hossein Ardeschir , Grimminger, Friedrich , Cajigas, Héctor , Brittain, Evan L , Seeger, Werner

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A7097-A7097

10.1164/ajrccm.2025.211.abstracts.a7097 Get It

Abstract Introduction Sex-based differences in morbidity and mortality for pulmonary hypertension (PH) are insufficiently addressed in current research. However, recognizing these differences is crucial for optimal clinical management and improving outcomes. This study assesses the effect of sex on survival among PH patients, while accounting for disease severity, comorbidities, treatment, and race. Methods We analyzed data from the PVRI GoDeep meta-registry, including all incident patients with complete hemodynamic profiles. Survival was evaluated using Kaplan-Meier and Cox proportional hazards models, adjusted for various confounders. Analyses included both PAH and non-PAH groups and risk assessment by the ESC/ERS 2022, REVEAL lite 2, and COMPERA 4-strata scores. All analyses were performed using R (The R Foundation). Results A total of 19,663 incident PH patients were included in the analysis, with 5,581 patients (28%) diagnosed with Group 1 PH and a median age of 64 years [IQR: 52-73]. Among these, male patients (8,704, 44%) had a significantly higher mortality risk than female patients across the entire cohort and within all PH subtypes. The adjusted hazard ratio for mortality in male versus female patients was 1.391 [95% CI: 1.260-1.536] in the overall population and 1.404 [95% CI: 1.264-1.561] for those with PAH. This survival difference was consistent across various severity levels, age groups, and in the presence of comorbidities such as obesity and cardiovascular diseases, as well as among those receiving PAH-specific therapies as well as patients who remained without treatment during the observation period. Notably, male disadvantage in survival was observed in low, intermediate, and high-risk categories for ESC/ERS 2022, REVEAL lite 2, and COMPERA scores but not within REVEAL 2.0, which includes male sex as a non-modifiable risk factor. Racial analysis revealed a greater mortality risk for males among White patients, with no significant differences noted in Black or Asian populations. Conclusion Our PVRI GoDeep meta-registry analysis demonstrates that male PH patients face higher mortality risk across both PAH and non-PAH groups, independent of disease etiology, age, severity, comorbidities, and treatment factors, with this risk amplified in White patients. These findings suggest that male sex should be further considered as a risk factor to refine predictive models for survival in PH.
Socio-demographic and Clinical Factors Associated With COVID-19 Vaccine Uptake Among Multiethnic US Adults: The C4R Study
Lawin, K., Norwood, Arnita F. , Stukovsky, Karen Hinckley , Elkind, Mitchell S, Ortega, Victor E. , Zhang, Ying , Fretts, Amanda M. , Oelsner, Elizabeth C. , Oelsner, Elizabeth C , Lawin, K., Wang, Timothy C. , Kucharska‐Newton, Anna , Demmer, Ryan T. , Jacobs, David R. , Regan, Elizabeth Anne , Lee, Joyce , Xanthakis, Vanessa , Isasi, Carmen R. , Kanaya, Alka M , Post, Wendy S. , Howard, Virginia J. , Lopez, V.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A7070-A7070

10.1164/ajrccm.2025.211.abstracts.a7070 Get It

Abstract RATIONALE: Deferral and declination of the COVID-19 vaccine is correlated with many factors, including different health guidelines and difficulties accessing the vaccine. In the US, COVID-19 vaccines were made available in tranches of clinical risk starting in December 2020 and were available to all adults on April 19, 2021. In the post-pandemic period, repeating COVID-19 vaccination with updated formulations is broadly recommended. Given that the public health impact of vaccine allocation strategies depends on public acceptance of vaccination, we aimed to evaluate demographic, clinical and social correlates of (1) receiving at least one COVID-19 vaccine by May 1, 2021 (prompt vaccination) and (2) the total number of vaccine doses received (vaccine count) through 2023-2024. METHODS: The Collaborative Cohort of Cohorts for COVID-19 Research (C4R) is a prospective observational meta-cohort study comprising 14 extant NIH-funded population-based cohorts. C4R assessed COVID-19 vaccination using three waves of standardized questionnaires (2020-2021, 2021-2023, 2023-2024). Prompt vaccination was defined by participant self-report of vaccination before May 1, 2021; participants vaccinated after May1, 2021 were classified as non-prompt; participants with missing vaccination information were excluded. Vaccine count was defined by self-report on the 2023-2024 wave Questionnaire. Demographic, clinical and social factors were classified by self-report and/or objective measures from the most recent pre-pandemic cohort exam. Poisson models regressed either prompt vaccination or vaccine count on pre-pandemic factors. RESULTS: Of 17,866 participants (mean age, 6713 years; 60.1% female; 42.1% non-Hispanic White, 22.0% Black, 28.9% Hispanic/Latino, 3.4% American Indian, 2.3% South Asian, 1.4% East Asian), 11,481 (64.3%) reported prompt vaccination. Of the subset of 14,529 participants completing the Wave 3 questionnaire, the median vaccine count in 2023-24 was 3 (Q1, 2; Q3 4). Likelihood of prompt vaccination was higher with greater age, income, and education and with history of diabetes and hypertension; prompt vaccination was less likely with male sex, current smoking, and non-White race and ethnicity (table). Similar associations were observed with respect to vaccine count (table). CONCLUSIONS: In a diverse C4R cohort community-based sample, earlier and greater COVID-19 vaccination was associated with older age and several clinical comorbidities; in contrast, later and lesser vaccine uptake was observed among historically marginalized groups. Whether disparities in COVID-19 vaccination could contribute to disparities in post-COVID-19 conditions merits further investigation.
Associations of SARS-COV-2 Infection and Long COVID With Respiratory Health in the Collaborative Cohort of Cohorts for COVID-19 Research (C4R) Study
Oelsner, Elizabeth C. , Jin, Y., Choi, Yuni , Lawin, K., Elkind, Mitchell S, Gallo, Linda C. , Stukovsky, Karen Hinckley , Newton, A. Kucharska, Norwood, Arnita F. , Ortega, Victor E. , Regan, E.A., Umans, Jason G. , Sun, Yifei , Oelsner, Elizabeth C , Balte, Pallavi , Wang, Timothy C. , Cushman, Mary , Demmer, Ryan T. , Howard, Virginia J. , Isasi, Carmen R. , Jacobs, David R. , Kanaya, Alka M , Lee, Joyce , Newton, Anna‐Kucharska , Gabriel, Kelley Pettee , Post, Wendy S. , Xanthakis, Vanessa

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A6349-A6349

10.1164/ajrccm.2025.211.abstracts.a6349 Get It

Abstract Rationale: SARS-CoV-2 infection may be associated with new or worsening respiratory symptoms that, if persistent, may contribute to “Long COVID.” Research is needed on the prevalence and risk determinants of Long COVID and related respiratory symptoms in adults with and without pre-existing obstructive lung disease or smoking history. Methods: C4R is a prospective, observational study that collected information on SARS-CoV-2 infection using standardized methods across 14 NIH-funded cohorts. The third wave of C4R questionnaires, administered June 2023 to January 2025, assessed self-reported Long COVID via the question, “Do you think that you are experiencing, or have ever experienced, what has been called “long COVID,” or symptoms related to COVID at least a month after your infection?” Questionnaires also assessed the presence (vs absence) of 22 symptoms that have been linked to Long COVID, including cough, shortness of breath, and post-exertional malaise. Pre-pandemic obstructive lung disease (COPD or asthma) and smoking status (ever/never) were harmonized from self-reported data collected at the most recent pre-pandemic cohort exam. Poisson regression was used to assess prevalence ratios (PRs) adjusting for age, sex, BMI, education, and pre-pandemic hypertension, diabetes, cardiovascular disease, and depressive symptoms. PRs for respiratory symptoms were tested according to self-reported Long COVID and history of non-hospitalized or hospitalized infection; effect modification by pre-pandemic lung disease and smoking was assessed by multiplicative interaction terms and in fully stratified models. Results: Among 23,434 questionnaire respondents, 1,484 (6.3%) self-reported Long COVID, including 246/1,262 (19.5%) with pre-pandemic lung disease and 664/4,018 (16.5%) with smoking history. The adjusted PR for Long COVID was 1.17 (95%CI:0.99-1.39;P=0.06) comparing participants with/without lung disease and 1.17 (95%CI:1.04-1.32;P=0.01) comparing participants with/without smoking history. Respiratory symptoms were more prevalent in those with self-reported Long COVID, as well as in those with a history of hospitalized or non-hospitalized infection (Table). Associations were generally stronger in participants without pre-pandemic lung disease (p-interaction&lt;0.05 for all comparisons). Respiratory symptoms were also more prevalent with a history of repeated, and pre-Omicron infections, and were less prevalent among participants vaccinated prior to their first infection; findings were similar even after excluding participants with self-reported Long COVID. Conclusions: Long COVID is common, particularly in adults with pre-existing COPD or asthma or smoking history. Long COVID and history of SARS-CoV-2 infection, including non-hospitalized infections, was associated with greater respiratory symptom burden. Whether SARS-CoV-2 infection or Long COVID are associated with development or progression of obstructive lung diseases warrants future studies.
Epigenomic and Transcriptomic Regulation of the MUC5B/MUC5AC Locus in Bronchial Airway Epithelium and Association With Early Small Airways Disease in Spiromics
Ortega, Victor E. , Chen, Xinyi , Shrivastav, A.K. , Zein, Joe , Howard, Timothy D. , Hawkins, Gregory A., Bowler, R.P., Comellas, Alejandro P. , Cooper, C.B. , Galbán, Craig J. , Hansel, Nadia N. , Hastie, Annette T. , Kanner, Richard E. , Martinez, F.J., Paine, Robert , Hoffman, E.A., Meyers, Deborah A. , Woodruff, P., Curtis, J.L., Bleecker, E.R., Christenson, S., C, NHLBI Subpopulations and Intermediate Outcomes Measures in, Christenson, Stephanie A. , Comellas, Alejandro P , Christenson, Stephanie A , Shrivastav, A.K., Barjaktarević, Igor , Barr, R. Graham , Couper, David , Han, MeiLan King , Kaner, Robert J. , Martinez, F.J., O’Neal, Wanda K. , Hoffman, E.A., Curtis, J.L., Huang, Yvonne J

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A5245-A5245

10.1164/ajrccm.2025.211.abstracts.a5245 Get It

Abstract Rationale: MUC5B and MUC5AC are neighboring genes on chromosome 11p15 that encode the two predominant mucins secreted in the respiratory airways. Increased airway mucin concentrations and an imbalance between these two mucins drive COPD symptoms and the development of airflow obstruction or COPD, but the epigenomic regulation of this loci has not been characterized in the airways. Methods: We isolated DNA from bronchial airway brushings of 72 participants with &gt;20 pack-years smoking history from the Subpopulations and Intermediate Outcomes Measures in COPD Study (SPIROMICS). 36 participants had GOLD-based moderate-to-severe COPD (FEV1/FVC&lt;0.70, FEV1&lt;80%) and 36 were without or with mild COPD. We used the Illumina Infinium Methylation EPIC BeadChip Array to assess proportion of DNA methylation (β) spanning 689,937 CpG sites. We evaluated proportional DNA methylation (β) at 96 CpG loci within a 103kB region using matrixQTL for cis-expression quantitative trait methylation (eQTM: 10kB flanks relative to MUC5AC/MUC5B) integrating bulk RNA-seq data and mQTL models integrating gene sequencing data to identify DNA variation associated with proportion eQTM methylation. Models included age, sex, BMI, clinical site, current smoking vs past smoking, total pack-years, three ancestral components of ancestry, chipset, and position. Results: We identified a top eQTM, cg00524486, marginally associated with MUC5B expression (coefficient estimate=8.75, punadjusted=0.0014, pFDR=0.065, Figure 1B). This eQTM was associated with CT scan parametric response mapping-based functional small airways disease (PRM-fSAD, beta coefficient[β]=3.64, p=0.011). We tested for DNA variation associated with methylation of this top eQTM which identified two methylation quantitative trait loci (mQTL: rs885454 [β=0.044, minor allele frequency[MAF]=0.09, pFDR=0.01], rs868902 [β=0.020, MAF=0.43, pFDR=0.08, Figure 1A) associated with cg00524486 methylation, of which the more frequent mQTL, rs868902, was marginally associated with PRM-fSAD (p=0.07) in the larger SPIROMICS cohort with MUC5B DNA sequencing data. Conclusions: This preliminary multi-omic study of the lower airway epithelium demonstrates that the expression of MUC5B is epigenetically regulated by neighboring CpG probe methylation (eQTM) represented by DNA variation (mQTL). These studies require further confirmation in a larger dataset of airway samples and support a role for epigenetic variation as a biologic contributor and biomarker of early COPD pathogenesis.
Albuterol-Budesonide Treatment in Acute Airway Obstruction: Patient Selection for the ALTA Study
Panettieri, Reynold A. , Wanner, A., Lipworth, BJ, Israel, E. , Meyers, Deborah A. , Ortega, Victor E. , Keith, M., Burnette, A.F., Gilbert, Ileen , Bleecker, Eugene R. , Akuthota, Praveen , Clarke, Graham W.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A1317-A1317

10.1164/ajrccm.2025.211.abstracts.a1317 Get It

Abstract RATIONALE: Albuterol-budesonide 180/160 µg is indicated in the US for as-needed treatment or prevention of bronchoconstriction and to reduce risk of exacerbations in patients ≥18 years old with asthma. The objective of the ALbuterol-budesonide Treatment in Acute airway obstruction (ALTA) study (NCT05555290) is to assess comparative efficacy, safety, and mechanisms of action of albuterol-budesonide 180/160 µg versus albuterol 180 µg in treating and preventing bronchoconstriction. This report describes the clinical profiles of patients meeting criteria for randomization into the trial. METHODS: ALTA is a phase 3b, multicenter, randomized, double-blind, 2-period, cross-over study evaluating the effects of repetitive dosing of albuterol-budesonide 180/160 µg versus albuterol 180 µg for treating adults treated as intermittent asthma and experiencing acute airway obstruction induced by repeated mannitol challenges. Inclusion criteria evaluated during screening include asthma diagnosis ≥6 months, prescribed and utilizing albuterol as the only asthma treatment for ≥4 weeks, pre-bronchodilator FEV1 ≥1.50 L and FEV1 ≥60% to &lt;90% predicted, and positive response to a mannitol challenge (decrease in FEV1≥15% at ≤635 mg cumulative mannitol dose). Exclusion criteria include clinically significant lung disease other than asthma; any smoking in the prior 6 months or ≥10 pack-year smoking history; or a clinical encounter for asthma worsening within the past 4 weeks. RESULTS: Thus far, 84 patients have met the criteria for randomization into ALTA. Mean(SD) age=44.9(13.7) years, 56.0% female, 40.5% African American, 9.5% Hispanic/Latino. Clinical characteristics include 10.7% with 1 prior-year severe exacerbation; mean(SD) fractional exhaled nitric oxide=37.0(37.4) ppb; mean(SD) baseline pre-bronchodilator FEV1=2.464(0.538) L; mean(SD) baseline percent predicted FEV1=76.7(7.9)%; mean(SD) % fall in FEV1 with mannitol challenge=22.1(7.3)% at a mean(SD) cumulative mannitol dose of 146.4(176.3) mg. Despite being treated for intermittent asthma, based upon symptoms, lung function, and exacerbation history, no patients met NAEPP 2007 criteria for intermittent disease, and 13.1% fell into the mild, 78.6% moderate, and 8.3% severe persistent asthma categories (Figure). With respect to asthma control, as measured by Asthma Impairment and Risk Questionnaire scores, 60.7% had well-controlled, 20.2% not well-controlled, and 19.1% very poorly controlled disease. CONCLUSION: The baseline characteristics of patients in the ALTA study reveal that patients treated as intermittent asthma exhibit heterogeneity in clinical characteristics, airway hyper-reactivity, T2 inflammation, and disease severity and control. Additional genomic and biomarker data are forthcoming and altogether will provide an opportunity to address the mechanism of albuterol and budesonide interactions in a broad spectrum of asthma phenotypes.
Sex differences in the executive and behavioral reserve of autosomal dominant frontotemporal dementia
Castro, J. García , Rubio‐Guerra, Sara , Casaletto, Kaitlin B. , Selma, Judit , Memel, Molly , Vaqué‐Alcázar, Lídia , Morcillo‐Nieto, Alejandra O. , Arriola‐Infante, José Enrique , Dols‐Icardo, Oriol , Bejanin, Alexandre , Belbin, Olivia , Carmona‐Iragui, María , Barroeta, Isabel , Santos‐Santos, Miguel , Saudinós, María Belen Sánchez, Sala, Isabel , Heuer, Hilary W. , Forsberg, Leah K. , Kantarci, Kejal, Staffaroni, Adam M. , Rankin, Katherine P. , Boxer, Adam L. , Rosen, Howard J. , Lleó, Alberto, Illán‐Gala, Ignacio , Kantarci, Kejal , Belbin, Olivia , Garcia Castro, Jesús , Illán-Gala, Ignacio , Bejanin, Alexandre , Kantarci, Kejal , Selma‐González, Judit , Fortea, Juan , Alcolea, Daniel , Sánchez‐Saudinós, María Belén , Tartaglia, Maria Carmela , Boeve, Bradley F. , Lleó, Alberto

Mayo Clinic

Alzheimer's & Dementia | April 25, 2025 | Volume: 21 | Issue: 4 | Pages: No page available

10.1002/alz.70070 | PMID 40277045 Get It

AbstractINTRODUCTIONSelf‐reported sex influences brain resilience, but its role in genetic frontotemporal dementia (FTD) remains unclear.METHODSWe analyzed 394 genetic‐FTD patients and 279 controls from the ALLFTD consortium, assessing annual neuropsychological performance and MRI‐based cortical thickness. Clinical characteristics and cortical thickness were compared between sexes. We used the residuals of linear regression models, which predict each participant's cognitive and behavioral performance levels relative to cortical thickness, as a proxy for reserve. We then modeled sex differences in longitudinal trajectories with linear mixed‐effects models.RESULTSSymptomatic females with genetic FTD had lower frontal cortical thickness than males, and the C9orf72 subgroup showed lower‐than‐expected frontal cortical thickness for a given level of executive functioning. Differences in cognitive reserve between sexes peaked near symptom onset but diminished thereafter.DISCUSSIONFemales with genetic FTD showed higher cognitive reserve than males, suggesting that self‐reported sex modulates resilience to frontotemporal neurodegeneration.Highlights Females with genetic FTD showed higher cognitive reserve than males. Those differences were particularly pronounced in the C9orf72 and GRN subgroups. The higher cognitive reserve in females declined as the disease progressed.
Sex differences in the clinical manifestation of autosomal dominant frontotemporal dementia
Memel, Molly , Staffaroni, Adam M. , Ilan‐Gala, Ignacio, Castro, J. García , Kornak, John , Tartaglia, Carmela M., Saloner, Rowan, Cadwallader, Claire J. , Chen, Coty , Gorno‐Tempini, Maria Luisa , Mandelli, Malu, Apostolova, Liana , Graff-Radford, N. R., Pressman, Peter , Miyagawa, Toji , Mackenzie, Ian R. , Darby, R. Ryan , Petrucelli, Len, Gendron, Tania, Heuer, Hilary W. , Forseberg, Leah K., Brushaber, Nellie, Domoto‐Reilly, Kimiko , Ghoshal, Nupur , Pascual, Belén , Lee, Suzee, Ramos, Eliana Marisa , Rademakers, Rosa , Rascovsky, Katya, Masdeu, Joseph C. , Boxer, Adam L., Rosen, Howard J. , Casaletto, Kaitlin B. , Illán‐Gala, Ignacio , Graff-Radford, Neil, Boeve, Brad F, Pascual, Belen , Domoto-Reilly, Kimiko , Garcia Castro, Jesús , Illán-Gala, Ignacio , Saloner, Rowan , VandeBunte, Anna M. , Paolillo, Emily W. , Litvan, Irene , Bayram, Ece , Goldman, Jill , Appleby, Brian S. , Gendron, Tania F. , Rojas, Julio C. , Boeve, Bradley F. , Lapid, Maria I. , Ramanan, Vijay K. , Pantelyat, Alexander , Masdeu, Joseph C , Snyder, Allison , Boxer, Adam L.

Mayo Clinic

Alzheimer's & Dementia | April 25, 2025 | Volume: 21 | Issue: 4 | Pages: No page available

10.1002/alz.14630 | PMID 40277077 Get It

Abstract INTRODUCTION Sex differences are apparent in neurodegenerative diseases but have not been comprehensively characterized in frontotemporal dementia (FTD). METHODS Participants included 337 adults with autosomal dominant FTD enrolled in the ALLFTD Consortium. Clinical assessments and plasma were collected annually for up to 6 years. Linear mixed‐effects models investigated how sex and disease stage are associated with longitudinal trajectories of cognition, function, and neurofilament light chain (NfL). RESULTS While sex differences were not apparent at asymptomatic stages, females showed more rapid declines across all outcomes in symptomatic stages compared to males. In asymptomatic participants, the association between baseline NfL and clinical trajectories was weaker in females versus males, a difference that was not present in symptomatic participants. DISCUSSION In genetic FTD, females show cognitive resilience in early disease stages followed by steeper clinical declines later in the disease. Baseline NfL may be a less sensitive prognostic tool for clinical progression in females with FTD‐causing mutations. Highlights Females with genetic FTD exhibit overall steeper increases in plasma neurofilament light chain (NfL) than males. Females with genetic FTD outperform NfL levels in asymptomatic stages compared to males. Once symptomatic, females with genetic FTD decline more rapidly than males. Plasma NfL is a stronger prognostic marker in asymptomatic males than females.
Approach to Lung Transplantation in Pulmonary Arterial Hypertension: A Delphi Consensus on Behalf of the Transplant Task Force of the Pulmonary Vascular Research Institute
Levine, Deborah J. , Castillo, Howard, Arcasoy, Selim M. , Benvenuto, Luke , Cevasco, Marisa , Demarest, Caitlin T. , Dewachter, Céline , Erasmus, Michiel E. , Glanville, Allan R. , Granton, John , Khangoora, Vikramjit, Krishnan, Sheila , Miltiades, Andrea , Murphy, Edward L. , Robbins, Ivan M. , Rahaghi, Franck , Saddoughi, Sahar A. , Vachiéry, Jean-Luc, Whitford, Helen, Girgis, Reda E. , Kolaitis, Nicholas A , Arcasoy, Selim M , Mercier, Olaf , Montani, David , Robbins, Ivan , Barnes, Hayley , Bacchetta, Matthew , Rosenzweig, Erika B. , Keshavjee, Shaf , Saddoughi, Sahar A. , Savale, Laurent , Simon, Marc A. , Vachiéry, Jean‐Luc , Ventetuolo, Corey E.

Mayo Clinic

Pulmonary Circulation | April 24, 2025 | Volume: 15 | Issue: 2 | Pages: No page available

10.1002/pul2.70088 | PMID 40276473 Get It

ABSTRACTLung transplantation is indicated for selected patients with advanced pulmonary arterial hypertension (PAH). We used a modified Delphi process to develop recommendations on care of patients with PAH undergoing lung transplantation. This Delphi panel was recruited from the Pulmonary Vascular Research Institute's Innovative Drug Discovery Initiative ‐ Lung Transplantation Workstream, consisting of clinical and research experts in PAH and lung transplantation. In this process, 29 panelists were given open‐ended questions, querying topics related to lung transplantation in PAH. A steering group converted the responses into discrete statements. Panelists then rated agreement using a Likert scale in two further survey rounds: −5 (strongly disagree) to 5 (strongly agree). Consensus was defined as mean ≥ 2.5 or ≤ −2.5, with a standard deviation not crossing zero. Consensus was reached on 141 of 223 statements. Notable areas of consensus were for early discussions about transplantation, and agreement with previously published referral and listing criteria. There was agreement that lung transplantation could be offered in sick candidates, including those with concurrent renal or hepatic insufficiency. Bilateral lung transplantation was considered the procedure of choice for most patients, with rare indications for heart‐lung transplantation. Consensus on bridging strategies included use of veno‐arterial extracorporeal membrane oxygenation and preemptive awake cannulation in those with severe right ventricular dysfunction. Consensus was also achieved on intraoperative use of invasive hemodynamic monitoring, and prolonged postoperative circulatory support guided by hemodynamic response and echocardiography. Patients with PAH undergoing transplantation require specialized management, which differs somewhat from other candidates.